AbbVie Inc (ABBV)vsMaravai Lifesciences Holdings Inc (MRVI)
ABBV
AbbVie Inc
$211.32
+3.64%
HEALTHCARE · Cap: $360.63B
MRVI
Maravai Lifesciences Holdings Inc
$3.68
+5.75%
HEALTHCARE · Cap: $542.79M
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 32827% more annual revenue ($61.16B vs $185.74M). ABBV leads profitability with a 6.9% profit margin vs -70.4%. ABBV earns a higher WallStSmart Score of 63/100 (C+).
ABBV
Buy63
out of 100
Grade: C+
MRVI
Avoid26
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-29.3%
Fair Value
$163.42
Current Price
$211.32
$47.90 premium
Margin of Safety
+42.2%
Fair Value
$5.40
Current Price
$3.68
$1.72 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Growing faster than its price suggests
Every $100 of equity generates 62 in profit
Strong operational efficiency at 34.1%
Conservative balance sheet, low leverage
Generating 4.9B in free cash flow
Conservative balance sheet, low leverage
Reasonable price relative to book value
Areas to Watch
6.9% margin — thin
Premium valuation, high expectations priced in
Earnings declined 88.7%
Distress zone — elevated risk
Smaller company, higher risk/reward
Weak financial health signals
ROE of -48.6% — below average capital efficiency
Revenue declined 11.8%
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, PEG Ratio, Return on Equity. PEG of 0.48 suggests the stock is reasonably priced for its growth.
Bull Case : MRVI
The strongest argument for MRVI centers on Debt/Equity, Price/Book.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 100.0x leaves little room for execution misses.
Bear Case : MRVI
The primary concerns for MRVI are Market Cap, Piotroski F-Score, Return on Equity.
Key Dynamics to Monitor
ABBV profiles as a value stock while MRVI is a turnaround play — different risk/reward profiles.
MRVI carries more volatility with a beta of 0.43 — expect wider price swings.
ABBV is growing revenue faster at 10.0% — sustainability is the question.
ABBV generates stronger free cash flow (4.9B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (63/100 vs 26/100). MRVI offers better value entry with a 42.2% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Maravai Lifesciences Holdings Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Maravai LifeSciences Holdings, Inc., a life sciences company, offers products to enable the development of drug therapies, diagnostics, novel vaccines, and to support human disease research in the United States and internationally. The company is headquartered in San Diego, California.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?